title: Monitoring disease activity and progression in Crohn's disease. A Swiss perspective on the IBD ahead 'optimised monitoring' recommendations.
abstract: OBJECTIVE
  The structured IBD Ahead 'Optimised Monitoring' programme was designed to obtain the opinion, insight and advice of gastroenterologists on optimising the monitoring of Crohn's disease activity in four settings: (1) assessment at diagnosis, (2) monitoring in symptomatic patients, (3) monitoring in asymptomatic patients, and (4) the postoperative follow-up. For each of these settings, four monitoring methods were discussed: (a) symptom assessment, (b) endoscopy, (c) laboratory markers, and (d) imaging. Based on literature search and expert opinion compiled during an international consensus meeting, recommendations were given to answer the question 'which diagnostic method, when, and how often'. The International IBD Ahead Expert Panel advised to tailor this guidance to the healthcare system and the special prerequisites of each country. The IBD Ahead Swiss National Steering Committee proposes best-practice recommendations adapted for Switzerland.
  
  
  METHODS
  The IBD Ahead Steering Committee identified key questions and provided the Swiss Expert Panel with a structured literature research. The expert panel agreed on a set of statements. During an international expert meeting the consolidated outcome of the national meetings was merged into final statements agreed by the participating International and National Steering Committee members - the IBD Ahead 'Optimized Monitoring' Consensus.
  
  
  RESULTS
  A systematic assessment of symptoms, endoscopy findings, and laboratory markers with special emphasis on faecal calprotectin is deemed necessary even in symptom-free patients. The choice of recommended imaging methods is adapted to the specific situation in Switzerland and highlights the importance of ultrasonography and magnetic resonance imaging besides endoscopy.
  
  
  CONCLUSIONS
  The recommendations stress the importance of monitoring disease activity on a regular basis and by objective parameters, such as faecal calprotectin and endoscopy with detailed documentation of findings. Physicians should not rely on symptoms only and adapt the monitoring schedule and choice of options to individual situations.
authors: GastroZentrum Hirslanden, Zurich, Switzerland.
authors: Bernhard
authors: B
authors: Sauter
authors: Christoph
authors: C
authors: Beglinger
authors: Marc
authors: M
authors: Girardin
authors: Andrew
authors: A
authors: Macpherson
authors: Pierre
authors: P
authors: Michetti
authors: Alain
authors: A
authors: Schoepfer
authors: Frank
authors: F
authors: Seibold
authors: Stephan R
authors: SR
authors: Vavricka
authors: Gerhard
authors: G
authors: Rogler
mesh_terms: D003424:Crohn Disease / Q000175:diagnosis*; D018450:Disease Progression; D016099:Endoscopy, Gastrointestinal; D006801:Humans